| Description |
SK33, a trifluoromethylated enobosarm analog, is a potent, and tissue selective anti-androgen. SK33reduces androgen receptor (AR) transcriptional activity[1].
|
| Related Catalog |
|
| In Vitro |
In LNCaPAR+ cells, SK33, demonstrates a significantly potent activity with IC50=0.2 μM. SK33 decreases cells entering S-phase in LNCaP cells. Treatment of LNCaP/BicR cells with increasing concentrations of SK33 for 96 hours results in a dose-dependent response and an inhibition of cell growth, with IC50 of approximately 5 μM for SK33[1]. Cell Viability Assay[1] Cell Line: LNCaP/BicR cells Concentration: 0.1-100 μM Incubation Time: 96 hours Result: Results in a dose-dependent response and an inhibition of cell growth.
|
| In Vivo |
SK33 (50 mg/kg; s.c.; 24 hours) inhibits AR transcriptional activity[1]. Animal Model: ARE-Luc mice[1] Dosage: 50 mg/kg Administration: Subcutaneously; 24 hours Result: Inhibited AR transcriptional activity.
|
| References |
[1]. Dart DA, et al. Novel Trifluoromethylated Enobosarm Analogues with Potent Antiandrogenic Activity In Vitro and Tissue Selectivity In Vivo.Mol Cancer Ther. 2018 Sep;17(9):1846-1858.
|
